ODAC Calls For Additional EPO Trials To Support Continued Use In Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
In the absence of data on approved therapeutic target, panel advises adding warnings from signals in off-label use to label.
You may also be interested in...
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups
Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC
Panel suggests new label saying the chemotherapy-induced anemia treatments are not indicated for patients with curable cancers, breast cancer or head and neck tumors.